CLINICAL_TRIALS trial_result · 2009-03-23

Clinical Trial Update: A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease [Phase 2, Phase 3]

A completed Phase 2/3 study of adalimumab (Humira) for inducing clinical remission in Japanese patients with Crohn's disease, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2009-03-23